: COVID-19 disease has a strong impact on hematological patients; those receiving autologous hematopoietic stem cell transplantation (aHSCT) represent a particularly vulnerable group, in which the effectiveness of vaccination is very variable. Chiarucci et al. showed that patients affected by non-Hodgkin lymphoma (NHL) and treated with rituximab experienced a lower rate of immunization against SARS-CoV-2 (54%), as well as significantly lower IgG antibody titers. In our multicenter retrospective observational study, we included 82 patients who underwent aHSCT, divided into two groups: 58 patients vaccinated after aHSCT (group A) and 24 vaccinated before getting transplantation (group B). In group A, 39 (67%) patients had positive serology, and the rate of positivity increased with time after aHSCT. In the subgroup of patients with NHL, the administration of rituximab predicted negative serology, particularly when administered in the 6 months before vaccination (13% response rate). Patients affected by plasma cells had a higher rate of positivity (83% overall), independently of the time to aHSCT. In group B, no patient who initially showed positive serology became negative after transplantation, so the aHSCT did not affect the response to the vaccination. Our study confirmed the role of rituximab as a negative predictor of response to SARS-CoV-2 vaccination, whereas the conditioning and transplantation procedure itself seemed to be less important.

Immunogenicity of SARS-CoV-2 vaccination in patients undergoing autologous stem cell transplantation. A multicentric experience / Autore, Francesco; Stirparo, Luca; Innocenti, Idanna; Papa, Elena; Marchesi, Francesco; Togni, Chiara; Mariani, Sabrina; Torrieri, Lorenzo; Salvatori, Martina; Fazio, Francesca; Metafuni, Elisabetta; Giammarco, Sabrina; Sora, Federica; Falcucci, Paolo; Ferrari, Antonella; Trisolini, Silvia Maria; Capria, Saveria; Tafuri, Agostino; Chiusolo, Patrizia; Sica, Simona; Laurenti, Luca. - In: FRONTIERS IN ONCOLOGY. - ISSN 2234-943X. - 12:(2022), p. 897937. [10.3389/fonc.2022.897937]

Immunogenicity of SARS-CoV-2 vaccination in patients undergoing autologous stem cell transplantation. A multicentric experience

Stirparo, Luca;Togni, Chiara;Mariani, Sabrina;Torrieri, Lorenzo;Salvatori, Martina;Fazio, Francesca;Capria, Saveria;Tafuri, Agostino;
2022

Abstract

: COVID-19 disease has a strong impact on hematological patients; those receiving autologous hematopoietic stem cell transplantation (aHSCT) represent a particularly vulnerable group, in which the effectiveness of vaccination is very variable. Chiarucci et al. showed that patients affected by non-Hodgkin lymphoma (NHL) and treated with rituximab experienced a lower rate of immunization against SARS-CoV-2 (54%), as well as significantly lower IgG antibody titers. In our multicenter retrospective observational study, we included 82 patients who underwent aHSCT, divided into two groups: 58 patients vaccinated after aHSCT (group A) and 24 vaccinated before getting transplantation (group B). In group A, 39 (67%) patients had positive serology, and the rate of positivity increased with time after aHSCT. In the subgroup of patients with NHL, the administration of rituximab predicted negative serology, particularly when administered in the 6 months before vaccination (13% response rate). Patients affected by plasma cells had a higher rate of positivity (83% overall), independently of the time to aHSCT. In group B, no patient who initially showed positive serology became negative after transplantation, so the aHSCT did not affect the response to the vaccination. Our study confirmed the role of rituximab as a negative predictor of response to SARS-CoV-2 vaccination, whereas the conditioning and transplantation procedure itself seemed to be less important.
2022
SARSC-CoV-2; autologous stem cell transplant (ASCT); efficacy; rituximab; vaccination
01 Pubblicazione su rivista::01a Articolo in rivista
Immunogenicity of SARS-CoV-2 vaccination in patients undergoing autologous stem cell transplantation. A multicentric experience / Autore, Francesco; Stirparo, Luca; Innocenti, Idanna; Papa, Elena; Marchesi, Francesco; Togni, Chiara; Mariani, Sabrina; Torrieri, Lorenzo; Salvatori, Martina; Fazio, Francesca; Metafuni, Elisabetta; Giammarco, Sabrina; Sora, Federica; Falcucci, Paolo; Ferrari, Antonella; Trisolini, Silvia Maria; Capria, Saveria; Tafuri, Agostino; Chiusolo, Patrizia; Sica, Simona; Laurenti, Luca. - In: FRONTIERS IN ONCOLOGY. - ISSN 2234-943X. - 12:(2022), p. 897937. [10.3389/fonc.2022.897937]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1696001
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact